Governance, risk and compliance is catching up with GW as it always would with a marketing based CEO. The newly appointed COO better enjoy his new seat while he still has it as well, not a great look, price queries, compliance issues, markets issues. Either the CEO and/or COO r responsible for that without question IMHO.
This is a good thing for the SRX SP, some blood on the floor in the quest of improving governance might become a very good advantage for SRX to have.
It has FCF, a good liver cancer treatment, 40% of its market, u would want to bulwark that down and hope that some fresh new ideas can get more success at the trials, primary treatments, PeterMacCullum/ ANU research projects and the like and move the company on a bit.
I think the ASX Query has almost ended GW as a credible CEO 4 SRX for the long term. IMHO that might become a great thing and improve SRX's growth with new bodies, new optimism, new survival rates and new markets. distribution.
Add to My Watchlist
What is My Watchlist?